Tumor angiogenic activity is an important process linked to tumor growth, metastasis, and invasion. In the present study we investigated whether intratumoral microvessel density (MVD), as assessed with immunohistochemistry, is of prognostic relevance in a series of 77 breast cancer patients with node-negative disease. The mean MVD in the hot spots ranged from 9 to 106 (median 31) vessels per x200 optical field. Patients were grouped into 3 categories of low (27 pts), medium (26 pts), and high (24 pts) MVD. Angiogenesis was not related to the primary tumor dimensions (T-stage) or the histology differentiation. An inverse association of MVD with estrogen receptor (ER) expression was noted (p=0.0007), while high MVD was directly related to c-erbB-2 overexpression (p=0.04) and high MIB 1 proliferation index (p=0.02). In univariate and multivariate analysis of relapse-free survival, MVD was the only variable significantly and independently linked to relapse. It is concluded that high intratumoral angiogenic activity is linked with early relapse in node-negative breast cancer.
1. Talks KL, Harris AL. Current status of antiangiogenic factors. Br J Haematol109:477-489, 2000
2.
2. Konerding MA, Miodonski AJ, Lametschwandtner A. Microvascular corrosion casting in the study of tumor vascularity: A review. Scanning Microsc9:1233-1243, 1995
3.
3. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet340:1120-1124, 1992
4.
4. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med324:1-8, 1991
5.
5. Locopo N, Fanelli M, Gasparini G. Clinical significance of angiogenic factors in breast cancer. Breast Cancer Res Treat52:159-173, 1998
6.
6. Peroulis I, Jonas N, Saleh M. Antiangiogenic activity of endostatin inhibits c6 glioma growth. Int J Cancer97:839-845, 2002
7.
7. Chekenya M, Hjelstuen M, Enger PO, Thorsen F, Jacob AL, Probst B, Haraldseth O, Pilkington G, Butt A, Levine JM, Bjerkvig R. NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J16:586-588, 2002
8.
8. Klijanienko J, el-Naggar AK, de Braud F, Rodriguezperalto JL, Rodriguez R, Itzhaki M, Russo A, Janot F, Luboinski B, Cvitkovic E. Tumor vascularization, mitotic index, histopathologic grade, and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas. Cancer75:1649-1656, 1995
9.
9. Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne K, Scott PA, Pezzella F, Georgoulias V, Harris AL, Gatter KC. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res4:3017-3024, 1998
10.
10. Aranda Fl, Laforga JB. Microvessel quantitation in breast ductal invasive carcinoma. Correlation with proliferative activity, hormonal receptors and lymph node metastases. Pathol Res Pract192:124-129, 1996
11.
11. Jacquemier JD, Penault-Llorca FM, Bertucci F, Sun ZZ, Houvenaeghel GF, Geneix JA, Puig BD, Bardou VJ, Hassoun JA, Birnbaum D, Viens PJ. Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: A multiparametric and immunohistochemical analysis. J Pathol184:130-135, 1998
12.
12. Charpin C, Devictor B, Bergeret D, Andrac L, Boulat J, Horschowski N, Lavaut MN, Piana L. CD31 quantitative immunocytochemical assays in breast carcinomas. Correlation with current prognostic factors. Am J Clin Pathol103:443-448, 1995
13.
13. Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, Meloche S, Alaoui-Jamali MA. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene19:3460-3469, 2000
14.
14. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor lalpha (HIF-lalpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol21:3995-4004, 2001
15.
15. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC, Harris AL. Relation of hypoxia-inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival. Br J Cancer85:881-890, 2001
16.
16. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Cox J, Krammer B, Gatter KC, Harris AL. bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. Clin Exp Metastasis17:545-554, 1999
17.
17. Yonenaga F, Takasaki T, Ohi Y, Sagara Y, Akiba S, Yoshinaka H, Aikou T, Miyadera K, Akiyama S, Yoshida H. The expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor is correlated to angiogenesis in breast cancer. Pathol Int48:850-856, 1998
18.
18. Claus EB, Chu P, Howe CL, Davison TL, Stern DF, Carter D, DiGiovanna MP. Pathobiologic findings in DCIS of the breast: Morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol70:303-316, 2001
19.
19. Bevilacqua P, Barbareschi M, Verderio P, Boracchi P, Caffo O, Dalla Palma P, Meli S, Weidner N, Gasparini G. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma-results of a multiparametric study. Breast Cancer Res Treat36:205-217, 1995
20.
20. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet340:1120-1124, 1992
21.
21. Ali SH, O'Donnell AL, Balu D, Pohl MB, Seyler MJ, Mohamed S, Mousa S, Dandona P. Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis. Cancer Res60:7094-7098, 2000
22.
22. Sivridis E, Giatromanolaki A, Koukourakis M, Anastasiadis P. Endometrial carcinoma: Association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch438:470-477, 2001
23.
23. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C. Vascular grading of angiogenesis: Prognostic significance in breast cancer. Br J Cancer82:339-347, 2000
24.
24. Gasparini G, Toi M, Biganzoli E, Dittadi R, Fanelli M, Morabito A, Boracchi P, Gion M. Thrombospondin-1 and -2 in node-negative breast cancer: Correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis. Oncology60:72-80, 2001
25.
25. Kato T, Kameoka S, Kimura T, Nishikawa T, Kasajima T. Angiogenesis and blood vessel invasion as prognostic indicators for node-negative breast cancer. Breast Cancer Res Treat65:203-215, 2001
26.
26. Colpaert C, Vermeulen P, Jeuris W, van Beest P, Goovaerts G, Weyler J, VanDam P, Dirix L, Van Marck E. Early distant relapse in “node-negative” breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumor. J Pathol193:442-449, 2001
27.
27. Vincent-Salomon A, Carton M, Zafrani B, Freneaux P, Nicolas A, Massernin B, Fourquet A, Clough K, Pouillart P, Sastre-Garau X. Long-term outcome of small size invasive breast carcinomas independent from angiogenesis in a series of 685 cases. Cancer92:249-256, 2001
28.
28. Vermeulen PB, Libura M, Libura J, O'Neill PJ, van Dam P, Van Marck E, Van Oosterom AT, Dirix LY. Influence of investigator experience and microscopic field size on microvessel density in nodenegative breast carcinoma. Breast Cancer Res Treat42:165-172, 1997
29.
29. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY. Quantification of angiogenesis in solid human tumors: An international consensus on the methodology and criteria of evaluation. Eur J Cancer32:2474-2484, 1996
